Open Trial Study Treatment with Agomelatine in Elderly Patients with Major Depressive Disorder with Hyponatremia Due to SSRI Use

Luis Alberto De La Garza,Andoni Gogeascoechea-Hernández,Jose Alfonso Ontiveros-Sanchez de la Barquera,Guillermo Sanchez-Torres,Sofia Jezzini-Martinez,Guillermo Porras-Garza,Patricio Zarate-Garza

DOI: https://doi.org/10.1016/j.jagp.2024.01.182

2024-04-01

Abstract:Introduction Hyponatremia, a condition where the blood has abnormally low levels of sodium, has been observed as a potential side effect in patients who receive treatment with Selective Serotonin Reuptake Inhibitors (SSRIs) antidepressants. This side effect can lead to hospitalization, death and is a significant cause for concern. Elderly patients are more prone to develop hyponatremia due to their age being a significant independent risk factor. Providing antidepressant treatment to this group of patients can be quite challenging due to the presence of multiple coexisting health conditions. Methods Patients with hyponatremia (60 years or older) related to their SSRI treatment (Escitalopram, Paroxetine, Sertraline, Fluvoxamine) for a major depressive disorder were selected. SSRI treatment was changed to Agomelatine 50 mg/day, and blood sodium levels were evaluated one month after the treatment. Also, MADRS and CGI of severity were used as an assessment of depressive symptoms before and after treatment with agomelatine. Results The mean age of our sample was 75.3 years (3 women, 2 men). Sodium levels while using ISRS were reported with a mean of 122.54 mEq/L. One case had severe hyponatremia (<120mEq/L), two moderate hyponatremias (120-129mEq/L), and one mild hyponatremia (130-134mEq/L). Mean MADRS and CGI scores on SSRIs before treatment with agomelatine were 27.8 and 5 respectively. After 4 weeks of treatment with agomelatine 50mg/day mean scores of sodium were reported at 135.48 mEq/L and mean MADRS and CGI scores at 13.6 and 2.4 respectively. No adverse events were observed during the agomelatine treatment. Differences in means of the MADRS scale before and after treatment with agomelatine were found to be statistically significant [27.8(3.89) vs 13.6 (8.35), p=<0.01]. Conclusions Our open trial study suggests that Agomelatine is a safe and effective treatment option for elderly patients who are afflicted by major depressive disorder and SSRI-induced hyponatremia. Nevertheless, additional studies involving larger patient samples will be necessary to confirm our findings.

psychiatry,geriatrics & gerontology,gerontology